GLP-1 patches side effects
You are dealing with a symptom and want to know if it is expected.
Reference and calculator, not medical advice. Dosing figures below are transcribed from FDA-approved prescribing information and link back to it. Last reviewed August 2026.
A point worth establishing first: there is no FDA-approved transdermal patch delivering semaglutide, tirzepatide or any other GLP-1 receptor agonist. Approved products are subcutaneous injections and, for semaglutide, an oral tablet. Products marketed as GLP-1 patches are not approved GLP-1 medications, whatever the marketing implies.
That distinction determines what can usefully be said about side effects. The effects documented for this drug class come from prescribing information for approved products at known doses via known routes. None of that transfers to an unapproved product of unknown composition.
Listed in the prescribing information
Common adverse reactions listed for GLP-1 receptor agonists as a class.
- NauseaMost commonly reported; typically worst after a dose increase.
- DiarrhoeaGastrointestinal effects are the most frequently listed category.
- VomitingReported more often at higher doses.
- ConstipationRelated to slowed gastric emptying.
- Abdominal painListed across the class.
- Injection site reactionsApplies to injectable products only.
- FatigueListed in product labelling.
- HeadacheListed in product labelling.
These products carry a boxed warning regarding thyroid C-cell tumours observed in rodent studies, and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Read the full prescribing information for your specific product and discuss it with your prescriber — this summary is not complete and is not a substitute for that document.
Common questions
- Why are these sold at all?
- Products marketed as patches generally sit outside the prescription drug framework, often as supplements or cosmetics, which is a different regulatory category with different requirements.
- How do I tell what an approved product is?
- Approved GLP-1 products carry prescribing information, require a prescription, and are administered by injection or as an oral tablet. Anything available without a prescription is not one of them.
- What are the real routes?
- Subcutaneous injection for semaglutide, tirzepatide, liraglutide and dulaglutide; an oral tablet for semaglutide (Rybelsus). That is the complete list of approved delivery routes.
Side-by-side
Structural facts from each product’s prescribing information.
| Product | Active ingredient | Indication | Frequency | Start | Max labelled | Steps to max |
|---|---|---|---|---|---|---|
| Zepbound Eli Lilly | Tirzepatide | Weight management | Weekly | 2.5 mg | 15 mg | 6 |
| Mounjaro Eli Lilly | Tirzepatide | Type 2 diabetes | Weekly | 2.5 mg | 15 mg | 6 |
| Wegovy Novo Nordisk | Semaglutide | Weight management | Weekly | 0.25 mg | 2.4 mg | 5 |
| Wegovy tablets Novo Nordisk | Semaglutide (oral) | Weight management | Daily | 1.5 mg | 25 mg | 4 |
| Ozempic Novo Nordisk | Semaglutide | Type 2 diabetes | Weekly | 0.25 mg | 2 mg | 4 |
| Rybelsus Novo Nordisk | Semaglutide (oral) | Type 2 diabetes | Daily | 3 mg | 14 mg | 3 |
| Saxenda Novo Nordisk | Liraglutide | Weight management | Daily | 0.6 mg | 3 mg | 5 |
| Trulicity Eli Lilly | Dulaglutide | Type 2 diabetes | Weekly | 0.75 mg | 4.5 mg | 4 |
Sources and last review
Every dosing figure on this page is transcribed from an FDA-approved label and links back to it. Conversions are arithmetic you can repeat by hand. Nothing here is reviewed by a clinician, and this site does not employ one — which is exactly why what I do publish stays traceable to its source.
- Zepbound (Tirzepatide) prescribing information — Eli Lilly, label revised 6 May 2026, checked 7 August 2026
- Mounjaro (Tirzepatide) prescribing information — Eli Lilly, label revised 6 May 2026, checked 7 August 2026
- Wegovy (Semaglutide) prescribing information — Novo Nordisk, label revised 30 June 2026, checked 7 August 2026
- Ozempic (Semaglutide) prescribing information — Novo Nordisk, label revised 10 June 2026, checked 7 August 2026
- Rybelsus (Semaglutide) prescribing information — Novo Nordisk, label revised 20 May 2026, checked 7 August 2026
- Saxenda (Liraglutide) prescribing information — Novo Nordisk, label revised 15 June 2026, checked 7 August 2026
- Trulicity (Dulaglutide) prescribing information — Eli Lilly, label revised 25 March 2026, checked 7 August 2026
Transcribed from the labels above and checked by me — Gavin, who builds this site, takes a GLP-1, and is not a clinician. Last reviewed August 2026. Found an error? [email protected] — I treat corrections as bugs. How this site is built and funded.
Citing this page
The figures here are transcribed from FDA-approved labels and each links to its source. If you are writing about this, quote the label rather than this site where you can — and if this page saved you the transcription, a link is appreciated.
Gavin. "GLP-1 patches side effects." GLP1Meter, reviewed August 2026. https://glp1meter.com/side-effects/glp-1-patches-side-effects/<a href="https://glp1meter.com/side-effects/glp-1-patches-side-effects/">GLP-1 patches side effects</a> — GLP1Meter, reviewed August 2026Gavin. (2026). GLP-1 patches side effects. GLP1Meter. Retrieved from https://glp1meter.com/side-effects/glp-1-patches-side-effects/
Also searched as: glp 1 patches side effects · side effects of glp-1 patches
Related
- GLP-1 side effectsSide effects
- GLP-1 long term side effectsSide effects
- GLP-1 side effects cancerSide effects
- Side effects of GLP-1 shotsSide effects
- Which GLP-1 has the least side effectsSide effects
- GLP-1 side effects redditSide effects
- GLP-1 tirzepatide side effectsSide effects
- How long do GLP-1 side effects lastSide effects